ALLO-SCAR is an executable clinical skill for transparent allopurinol severe cutaneous adverse reaction risk-context stratification before initiation or during early toxicity assessment. The model integrates HLA-B*58:01 status, ancestry context, chronic kidney disease, allopurinol dose, diuretic exposure, cardiovascular comorbidity or hypertension, prior rash, timing since start, and early warning signs including fever, facial edema, mucosal involvement, eosinophilia, transaminitis, and creatinine rise.
Thiopurines remain clinically useful across rheumatology and systemic autoimmune disease, but preventable myelotoxicity still occurs when pharmacogenetic risk, baseline blood counts, interacting medications, and monitoring readiness are reviewed separately instead of together. We present THIO-SAFE, a transparent 10-domain weighted bedside score for estimating near-term azathioprine myelotoxicity risk.
LATAM-RX adjusts rheumatology clinical decision support for Latin American practice realities including TB burden, insurance formulary limitations (IMSS/ISSSTE), endemic infection screening, diagnostic delays, and access fragility. Four-domain composite with GLADEL/PANLAR/COPCORD references.
RIESGO-LAT integrates population-specific allele frequencies (CYP2C19, HLA-B*5801, SLCO1B1, CYP2D6) with traditional CV risk factors for pharmacogenomic-adjusted cardiovascular risk assessment in Latin American populations. Uses PharmGKB/1000 Genomes allele frequency data with CPIC guideline-based drug-gene interaction detection (clopidogrel, allopurinol, simvastatin, metoprolol).
RIESGO-LAT integrates population-specific allele frequencies (CYP2C19, HLA-B*5801, SLCO1B1, CYP2D6) with traditional CV risk factors for pharmacogenomic-adjusted cardiovascular risk assessment in Latin American populations. Uses PharmGKB/1000 Genomes allele frequency data with CPIC guideline-based drug-gene interaction detection (clopidogrel, allopurinol, simvastatin, metoprolol).
We present a proof-of-concept protocol for prospective validation of the STORM pharmacogenomic decision-support calculator in a 607-patient cohort at Hospital General Regional No. 1, IMSS, Mérida, Yucatán, Mexico.
AEGIS (Adverse Event & Gene Intelligence System) is an open-source pharmacovigilance module that integrates openFDA FAERS adverse event data, FDA approval status, off-label use detection, and pharmacogenomic risk profiles for drugs used in rheumatology. The system provides real-time signal detection across 39 rheumatological drugs, cross-referencing adverse event reports with gene-drug interactions from CPIC and PharmGKB.
STORM (Stochastic Therapy Optimization for Rheumatology in Mexico) v3.1 is a pharmacogenomic decision-support calculator implementing ancestry-stratified allele frequency interpolation across 18 genes, 39 drugs, and 11 rheumatic diseases.
RIESGO-LAT is a pharmacogenomic-adjusted stochastic risk model for cardiovascular and metabolic outcomes in Latino populations with Type 2 Diabetes and Hypertension. Uses Monte Carlo simulation (10,000 trajectories) with stochastic differential equations calibrated against ENSANUT 2018-2022 and MESA Latino subgroup data.